3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Medullary
3
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Interventions
pembrolizumab
72
Cisplatin
57
Cetuximab
38
Fluorouracil
25
Nivolumab
21
Radiotherapy
20
Carboplatin
19
Paclitaxel
14
Docetaxel
11
Cyclophosphamide
9
Gefitinib
8
fludarabine
7
durvalumab
7
zalutumumab
6
atezolizumab
6
Drug Therapy
6
Bleomycin
6
epacadostat
5
cemiplimab
5
Radiotherapy, Intensity-Modulated
5
Pemetrexed
5
Ipilimumab
5
Gemcitabine
5
Afatinib
5
spartalizumab
4
Standard of Care
4
Radiation
4
Injections
4
Immune Checkpoint Inhibitors
4
Fibroblast Growth Factor 7
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Head and Neck Neoplasms
×
pralsetinib
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA